Chlorthalidone Blood Pressure Medication Recalled Nationwide Over Manufacturing Quality Issue
Over 11,400 bottles of the blood pressure medication chlorthalidone have been recalled nationwide after testing revealed manufacturing defects that may reduce the drug's effectiveness. The FDA classified it as a moderate hazard.
Widespread Blood Pressure Medication Recall
Thousands of bottles of a popular blood pressure medication have been recalled nationwide due to a potential manufacturing issue that may affect how well the drug works. According to the U.S. Food and Drug Administration, more than 11,400 bottles of prescription chlorthalidone pills are affected.
Manufacturing Issue Details
On June 5, the drug's manufacturer, India-based Inventia Healthcare Limited, initiated a voluntary recall of certain lots of its 25-mg chlorthalidone tablets. The recalled 100-count and 1,000-count bottles were distributed across the U.S. by Rising Pharma Holdings, Inc., of New Jersey. The recall was issued after testing revealed that certain lots of the medication "failed dissolution specifications," per the FDA.
FDA Classification
On June 22, the FDA classified the recall as a moderate hazard or "Class II," which is defined as a situation where use of the recalled product may cause temporary or medically-reversible adverse health effects.
What Is Chlorthalidone?
Chlorthalidone is a common diuretic medication used to treat high blood pressure and fluid retention. It works by helping the kidneys get rid of excess water and salt in the body and excrete them through urine.
Patient Safety Concerns
Always consult with a medical professional before discontinuing prescription medication. Abruptly stopping taking blood pressure medication can have side effects and serious health risks. Patients should check their medication bottles against the FDA's list of specific NDC codes and batch numbers to determine if their supply is affected.
Pattern of Recalls
This is the second recall of a commonly-prescribed blood pressure medication to occur in less than a year. In October 2025, more than half a million bottles of prazosin hydrochloride were recalled over concerns that the capsules contained unsafe levels of cancer-causing chemicals.